HYBRID EVENT: Join us in person in Tokyo, Japan or attend virtually from anywhere.
Retinoblastoma, a rare and aggressive eye cancer affecting the retina, often requires a multifaceted approach to treatment. Chemotherapy stands as a crucial component in the battle against this malignancy, aiming to shrink tumors and impede cancer cell growth. Systemic chemotherapy involves administering drugs intravenously or orally, allowing them to circulate throughout the body. The medications utilized in retinoblastoma chemotherapy may include vincristine, etoposide, and carboplatin. These drugs work synergistically to disrupt the abnormal cell division characteristic of cancer, hindering the progression of retinoblastoma. Intravitreal chemotherapy presents another method, involving the injection of chemotherapeutic agents directly into the vitreous cavity of the eye. This localized approach targets cancer cells within the eye while minimizing systemic exposure. Melphalan and topotecan are commonly used in intravitreal chemotherapy for retinoblastoma. Combination therapy, incorporating both systemic and intravitreal approaches, may be employed to maximize treatment efficacy. The choice of chemotherapy regimen depends on factors such as the extent of tumor involvement, the presence of genetic mutations, and the overall health of the patient. Despite its efficacy, chemotherapy for retinoblastoma is not without potential side effects. Patients may experience nausea, fatigue, and a heightened susceptibility to infections. Monitoring and managing these side effects are integral aspects of the overall treatment strategy. Regular assessments, including imaging studies and eye examinations, help gauge the response to chemotherapy. Adjustments to the treatment plan may be made based on the tumor's response and any emerging side effects. The collaborative efforts of oncologists, ophthalmologists, and support teams are crucial in navigating the complexities of retinoblastoma chemotherapy and optimizing outcomes for affected individuals.
